Journal: medRxiv
Article Title: Early economic evaluation of a predictive tool to test CFTR modulator treatment response in people with cystic fibrosis
doi: 10.64898/2026.01.12.26343787
Figure Lengend Snippet: The plot visualizes the impact of variation of individual parameters on the incremental cost-eAectiveness ratio by alternately varying input values between 80% (min, blue) and 120% (max, red) of their original value. CFTR = Cystic Fibrosis Transmembrane conductance Regulator, PEX = pulmonary exacerbation, ICER = Incremental Cost-EAectiveness Ratio.
Article Snippet: Costs for SoC, CFTR modulator treatment (ETI, Trikafta®/Kaftrio®) by Vertex Pharmaceuticals Incorporated, Boston, MA, USA) and PEX-events were calculated using public list prices and reference prices from the Dutch Healthcare Institute and the Dutch Healthcare Authority [ - ].
Techniques: